Dexcom Appoints Jon Coleman as Chief Commercial Officer

Rhea-AI Summary

Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, has appointed Jon Coleman as Chief Commercial Officer. Coleman brings over 30 years of global commercial leadership experience and will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.

Coleman previously served as an executive officer at Masimo (NASDAQ: MASI) for 15 years, where he was president of commercial teams. He managed worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service. Prior to Masimo, Coleman held leadership positions at Pfizer (NYSE: PFE) Consumer Healthcare, including vice president and general manager of Canada and the Caribbean region, with additional experience in Asia and Latin America.

Throughout his career, Coleman has demonstrated success in scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

Positive

• Appointment of experienced executive with 30+ years of global commercial leadership
• Strong track record in scaling operations and entering new markets
• Extensive experience in healthcare across multiple segments and channels
• Proven history of delivering growth performance

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience.

Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ: MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo’s commercial teams where he oversaw the consolidation of its worldwide hospital sales, OEM, alternate care sales, and clinical teams along with the customer service and hospital conversion teams. Mr. Coleman also held significant roles at Pfizer’s (NYSE: PFE) Consumer Healthcare business, leading as vice president and general manager of Canada and the Caribbean region after several years of regional leadership in Asia and Latin America. Across his various roles at these organizations, Mr. Coleman established a track record of scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

“Jon has demonstrated the ability to lead organizations through the complexities of global healthcare with consistently strong performance across a variety of sectors and channels,” said Kevin Sayer, chairman, president and chief executive officer at Dexcom. “This broad experience across market segments and regions provides a great fit as we look to capitalize on Dexcom’s incredible growth opportunity.”

“Dexcom’s commitment to drive innovation in glucose biosensing and its unique long-term growth opportunity make the chief commercial officer role an incredible opportunity,” said Mr. Coleman. “I am excited to lead this great team at a key point in the company’s history and execute on the company’s ambitious vision to empower greater health around the world.”

About Jon Coleman

Prior to his role as president – Worldwide OEM & Global Health at Masimo, Mr. Coleman held several roles of increasing responsibility at Masimo including president – Worldwide Sales, Professional Services, Medical Affairs, and OEM and president – International. Before joining Masimo, he was general manager – Americas region for Targus Group International, Inc. Before that, Mr. Coleman spent more than a decade in leadership of the Consumer Healthcare business at Pfizer, revitalizing growth as vice president and general manager – Canada and Caribbean region and driving double-digit growth as region director – Asia. Before joining Pfizer, Mr. Coleman began his career with roles at the Procter & Gamble Company and Bain & Company.

Mr. Coleman earned an M.B.A. from Harvard Business School and a Bachelor of Arts degree in International Relations from Brigham Young University.

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250325396614/en/

Media Contact

James McIntosh

619-884-2118

mediarelations@dexcom.com



Investor Contact

Sean Christensen

858-203-6657

investor-relations@dexcom.com

Source: DexCom, Inc.

FAQ

What role will Jon Coleman take at Dexcom (DXCM) and what are his responsibilities?

Jon Coleman is appointed as Chief Commercial Officer at Dexcom, responsible for managing the global commercial organization, including global sales, marketing, and customer experience.

What is Jon Coleman's previous experience before joining Dexcom (DXCM)?

Coleman has 30+ years of global commercial leadership experience, including 15 years at Masimo as president of commercial teams and leadership roles at Pfizer Consumer Healthcare.

How does Jon Coleman's appointment align with Dexcom's (DXCM) growth strategy?

Coleman's broad experience across market segments and regions positions Dexcom to capitalize on growth opportunities, leveraging his track record of scaling operations and entering new markets.

What were Jon Coleman's key achievements at Masimo before joining Dexcom (DXCM)?

At Masimo, Coleman oversaw the consolidation of worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service operations as president of commercial teams.